Reviewed October 2015
What is the official name of the KRAS gene?
The official name of this gene is “Kirsten rat sarcoma viral oncogene homolog.”
KRAS is the gene's official symbol. The KRAS gene is also known by other names, listed below.
Read more about gene names and symbols on the About page.
What is the normal function of the KRAS gene?
The KRAS gene provides instructions for making a protein called K-Ras that is involved primarily in regulating cell division. As part of a signaling pathway known as the RAS/MAPK pathway, the protein relays signals from outside the cell to the cell's nucleus. These signals instruct the cell to grow and divide or to mature and take on specialized functions (differentiate). The K-Ras protein is a GTPase, which means it converts a molecule called GTP into another molecule called GDP. The K-Ras protein acts like a switch, and it is turned on and off by the GTP and GDP molecules. To transmit signals, the K-Ras protein must be turned on by attaching (binding) to a molecule of GTP. The K-Ras protein is turned off (inactivated) when it converts the GTP to GDP. When the protein is bound to GDP, it does not relay signals to the cell's nucleus.
The KRAS gene belongs to a class of genes known as oncogenes. When mutated, oncogenes have the potential to cause normal cells to become cancerous. The KRAS gene is in the Ras family of oncogenes, which also includes two other genes: HRAS and NRAS. The proteins produced from these three genes are GTPases. These proteins play important roles in cell division, cell differentiation, and the self-destruction of cells (apoptosis).
How are changes in the KRAS gene related to health conditions?
cardiofaciocutaneous syndrome - caused by mutations in the KRAS gene
Mutations in the KRAS gene are an uncommon cause of cardiofaciocutaneous syndrome, accounting for less than 5 percent of cases. Several mutations in this gene have been identified in people with characteristic features of the disorder, which include heart defects, distinctive facial features, and skin abnormalities. The mutations change single protein building blocks (amino acids) in the K-Ras protein. The altered protein shows increased GTP binding and a decreased ability to convert GTP to GDP. These effects lead to prolonged activation of the K-Ras protein, which alters tightly regulated RAS/MAPK signaling during development. The altered signaling interferes with the development of organs and tissues throughout the body, leading to the varied signs and symptoms of cardiofaciocutaneous syndrome.
Noonan syndrome - caused by mutations in the KRAS gene
Mutations in the KRAS gene have caused a small number of cases of severe or atypical Noonan syndrome, a condition that affects many parts of the body. Intellectual disability is more common in people who have Noonan syndrome with a KRAS gene mutation than in people with Noonan syndrome caused by a mutation in a different gene.
The KRAS gene mutations associated with Noonan syndrome change single amino acids in a critical region of the K-Ras protein. The resulting protein is overactive, with increased GTP-binding and a decreased ability to convert GTP to GDP. The abnormally active protein alters normal RAS/MAPK signaling and disrupts the development of organs and tissues throughout the body. Researchers believe that increased K-Ras activation leading to defective cell movement and differentiation could play a role in the signs and symptoms of Noonan syndrome, including short stature, heart defects, and skeletal abnormalities.
Rarely, people with Noonan syndrome caused by a KRAS gene mutation will also develop juvenile myelomonocytic leukemia, which is a type of blood cancer that typically affects children or adolescents.
lung cancer - associated with the KRAS gene
At least three mutations in the KRAS gene have been associated with lung cancer, a disease in which certain cells in the lung become abnormal and multiply uncontrollably to form a tumor. These mutations are somatic, which means they are acquired during a person's lifetime and are present only in tumor cells. Somatic mutations are not inherited. Nearly all of the KRAS gene mutations associated with lung cancer change the amino acid glycine at position 12 or 13 (Gly12 or Gly13) or change the amino acid glutamine at position 61 (Gln61) in the K-Ras protein. These mutations lead to a K-Ras protein that is constantly turned on (constitutively activated) and directing cells to grow and divide in an uncontrolled way, leading to tumor formation. When these gene changes occur in cells in the lungs, lung cancer develops.
KRAS gene mutations are found in 15 to 25 percent of all lung cancer cases but are more frequent in affected white populations compared to affected Asian populations; 25 to 50 percent of whites with lung cancer have KRAS gene mutations, whereas 5 to 15 percent of Asians with lung cancer have KRAS gene mutations.
While genetic, environmental, and lifestyle factors, including long-term tobacco smoking, contribute to a person's cancer risk, KRAS gene mutations are much more common in nonsmokers with lung cancer than in smokers. Lung cancers with KRAS gene mutations typically indicate a poor prognosis and resistance to several cancer treatments.
- other disorders - caused by mutations in the KRAS gene
KRAS gene mutations also cause a disorder whose major features overlap with those of Noonan syndrome, cardiofaciocutaneous syndrome, and a related disorder called Costello syndrome. This condition has been described as the KRAS mutation-associated phenotype. People with this condition have variable signs and symptoms that include mild to moderate intellectual disability, distinctive facial features, short stature, an unusually large head (macrocephaly), and hair that is sparse and thin.
At least nine mutations in the KRAS gene have been reported in people with this disorder. These mutations are present in all of the body's cells and are known as germline mutations. Each of these mutations changes single amino acids in the K-Ras protein. These genetic changes abnormally activate the protein, which alters chemical signaling in cells throughout the body. The altered signaling interferes with the normal development of many organs and tissues, resulting in the characteristic features of the KRAS mutation-associated phenotype.
- other cancers - increased risk from variations of the KRAS gene
Somatic mutations in the KRAS gene are involved in the development of several types of cancer, particularly pancreatic and colorectal cancers. These mutations lead to a K-Ras protein that is more strongly overactivated than the mutations that cause cardiofaciocutaneous syndrome and Noonan syndrome (described above). The abnormal K-Ras protein is always active and can direct cells to grow and divide in an uncontrolled way.
Genetics Home Reference provides additional information about these conditions associated with changes in the KRAS gene:
Where is the KRAS gene located?
Cytogenetic Location: 12p12.1
Molecular Location on chromosome 12: base pairs 25,204,789 to 25,250,931
(Homo sapiens Annotation Release 107, GRCh38.p2) (NCBI
The KRAS gene is located on the short (p) arm of chromosome 12 at position 12.1.
More precisely, the KRAS gene is located from base pair 25,204,789 to base pair 25,250,931 on chromosome 12.
See How do geneticists indicate the location of a gene? in the Handbook.
Where can I find additional information about KRAS?
You and your healthcare professional may find the following resources about KRAS helpful.
You may also be interested in these resources, which are designed for genetics professionals and researchers.
What other names do people use for the KRAS gene or gene products?
- cellular c-Ki-ras2 proto-oncogene
- c-Kirsten-ras protein
- c-K-ras2 protein
- c-K-ras protein
- Kirsten rat sarcoma-2 viral (v-Ki-ras2) oncogene homolog
- K-ras p21 protein
- PR310 c-K-ras oncogene
- transforming protein p21
- v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog
- v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog
Where can I find general information about genes?
The Handbook provides basic information about genetics in clear language.
These links provide additional genetics resources that may be useful.
What glossary definitions help with understanding KRAS?
The resources on this site should not be used as a substitute for
professional medical care or advice. Users seeking information about
a personal genetic disease, syndrome, or condition should consult with a qualified
See How can I find a genetics professional in my area? in the Handbook.